Order results by:
| Issue | Title | |
| Vol 16, No 5 (2020) | The CES1 Gene rs2244613 Minor Allele Impact on the Safety Profile of Dabigatran Etexilate: Meta-Analysis | Abstract similar documents |
| S. P. Abdullaev, K. B. Mirzaev, P. O. Bochkov, I. N. Sychev, D. A. Sychev | ||
| "... 2244613 reduces the risk of any bleeding during dabigatran taking, however, no significant association ..." | ||
| Vol 17, No 1 (2021) | Pharmacokinetics and Pharmacogenetics of Dabigatran | Abstract similar documents |
| A. V. Savinova, V. S. Dobrodeeva, M. M. Petrova, R. F. Nasyrova, N. A. Shnayder | ||
| "... Dabigatran etexilate is a prodrug of dabigatran, a oral direct inhibitor of thrombin ..." | ||
| Vol 16, No 2 (2020) | The Risk of Myocardial Infarction in Patients with Atrial Fibrillation Taking a Direct Thrombin Inhibitor: Myths and Reality | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| "... of cohort and observational studies in real clinical practice on the influence of dabigatran etexilate ..." | ||
| Vol 12, No 5 (2016) | Dabigatran Etexilate in the course of Electrical Cardioversion in Patients with Non-Valvular Atrial Fibrillation | Abstract similar documents |
| N. A. Novikova, A. N. Volovchenko | ||
| "... events in patients with AF. Possibility to perform planned cardioversion while receiving dabigatran has ..." | ||
| Vol 13, No 3 (2017) | PHARMACOGENETIC ASPECTS OF NEW ORAL ANTICOAGULANTS APPLICATION | Abstract similar documents |
| A. V. Kryukov, D. A. Sychev, O. V. Tereshchenko | ||
| "... on the pharmacokinetics of these drugs. RE-LY study showed a 15% decrease in trough dabigatran concentration and 27% lower ..." | ||
| Vol 8, No 6 (2012) | HOW TO USE DABIGATRAN IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| S. V. Moiseev | ||
| "... Dabigatran is the new oral anticoagulant that directly inhibits thrombin (factor IIa). In RE-LY ..." | ||
| Vol 16, No 6 (2020) | An Elderly Comorbid Patient with Atrial Fibrillation: What is Important to Know and What Should be Considered When Prescribing Anticoagulants? | Abstract similar documents |
| T. V. Pavlova | ||
| "... нескольких больших мета-анализов, которые свидетельствуют о снижении у пациентов частоты развития сердечно ..." | ||
| Vol 7, No 1 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: NEW DATA AND NEW HORIZONS | Abstract similar documents |
| M. Yu. Gilyarov, V. A. Sulimov | ||
| "... are considered. Special attention are paid to the direct thrombin inhibitors — dabigatran. Possibilities ..." | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov, G. Yu. Trufanova | ||
| Vol 15, No 2 (2019) | Studies of Anticoagulant Therapy in Frail Elderly Patients: Problems of Terminology and Methodology | Abstract similar documents |
| Sergey N. Bel'diev, Irina V. Medvedeva, Dmitry Yu. Platonov, Galina Yu. Trufanova | ||
| Vol 9, No 5 (2013) | PRACTICAL APPLICATION OF DABIGATRAN ETEXILATE FOR STROKE PREVENTION IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| E. D. Kosmacheva, S. G. Kanorskiy, A. A. Kastanayan, N. V. Haylo, D. B. Goltyapin, E. A. Lipnitskaya, M. E. Statsenko | ||
| "... dabigatran etexilate, in the stroke prevention in patients with atrial fibrillation are considered. Factors ..." | ||
| Vol 18, No 5 (2022) | Thrombocytopenia Induced by Direct Oral Anticoagulants: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova | ||
| "... thrombin blockers (dabigatran) or factor IIa blockers (apixaban, rivaroxaban, edoxaban). According ..." | ||
| Vol 13, No 5 (2017) | DRUG INTERACTIONS OF NEW ORAL ANTICOAGULANTS: INSIDE AND OUTSIDE TABLE CELLS | Abstract similar documents |
| S. N. Bel'diev, I. V. Medvedeva, D. Yu. Platonov | ||
| Vol 7, No 6 (2011) | DABIGATRAN ETEXILATE FOR PREVENTION OF CARDIOEMBOLIC COMPLICATIONS IN NONVALVULAR ATRIAL FIBRILLATION: HOW TO DO THE INTERVENTION MORE EFFECTIVE AND SAFER | Abstract similar documents |
| I. S. Yavelov | ||
| "... Application of dabigatran etexilate for prevention of cardioembolic complications in nonvalvular ..." | ||
| Vol 13, No 5 (2017) | Drug interactions of non-vitamin K antagonist oral anticoagulants: inside and outside table cells | Abstract similar documents |
| Sergey Nikolaevich Bel'diev, Irina Vladimirovna Medvedeva, Dmitry Jur'evich Platonov | ||
| Vol 17, No 2 (2021) | Dynamics of Kidney Function in Patients with Chronic Kidney Disease and Atrial Fibrillation Who Receive Dabigatran | Abstract PDF (Eng) similar documents |
| N. A. Novikova, Z. K. Salpagarova, M. I. Chashkina, A. A. Bykova, Z. A. Alimova, А. S. Yadykina, D. F. Mesitskaya, N. A. Babakova, D. A. Andreev | ||
| "... of the anticoagulant therapy in the outpatient practice. Initially, 133 dabigatran taking patients were enrolled ..." | ||
| Vol 18, No 3 (2022) | Clinically Significant Drug Interactions for Direct Oral Anticoagulants: State of the Art | Abstract similar documents |
| S. R. Gilyarevsky | ||
| "... interactions of apixaban, rivaroxaban and dabigatran with the drugs most frequently used in patients ..." | ||
| Vol 12, No 2 (2016) | THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION IN CLINICAL PRACTICE | Abstract similar documents |
| S. V. Moiseev | ||
| "... (dabigatran), today are increasingly replacing warfarin and other indirect anticoagulants in preventing stroke ..." | ||
| Vol 12, No 4 (2016) | Clinical significance of new oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation: not all dreams come true | Abstract similar documents |
| Yu. A. Bunin, S. V. Miklishanskaya | ||
| Vol 13, No 1 (2017) | DATA OF CLINICAL PRACTICE AS A TOOL FOR CHOICE OF DIRECT ORAL ANTICOAGULANT | Abstract similar documents |
| D. А. Napalkov, A. A. Sokolova, V. V. Fomin | ||
| Vol 7, No 5 (2011) | ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION: RECENT APPROACHES AND NEAR PERSPECTIVES | Abstract similar documents |
| Ya. P. Dovgalevskiy, L. E. Kuvshinova, I. V. Graifer, N. V. Furman, P. Ya. Dovgalevskiy | ||
| Vol 9, No 3 (2013) | ANTICOAGULANT THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: DRUG CHOICE AND DOSAGE ADJUSTMENT | Abstract similar documents |
| E. L. Dolgova, I. M. Sokolov, Yu. G. Shvarts | ||
| Vol 11, No 3 (2015) | ANALYSIS OF THE INFLUENCE OF THROMBOEMBOLIC COMPLICATIONS PREVENTION WITH ORAL ANTICOAGULANTS ON BUDGET IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... administration of vitamin K antagonists (warfarin) or the new oral anticoagulants (apixaban, dabigatran ..." | ||
| Vol 9, No 4 (2013) | COMPARISON OF DIRECT COSTS OF DABIGATRAN AND WARFARIN THERAPY IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION DURING PREPARATION FOR ELECTIVE CARDIOVERSION IN THE REAL CLINICAL PRACTICE | Abstract similar documents |
| L. E. Kuvshinova, N. V. Furman, P. V. Dolotovskaya, Ya. P. Dovgalevsky | ||
| "... Aim. To compare direct medical costs of dabigatran and warfarin therapy in patients with non ..." | ||
| Vol 9, No 4 (2013) | COMPARATIVE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS | Abstract similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova | ||
| Vol 10, No 4 (2014) | NEW ORAL ANTICOAGULANTS: FOCUS ON THE SAFETY | Abstract similar documents |
| D. A. Napalkov, A. A. Sokolova | ||
| "... dabigatran, rivaroxaban and apixaban) is presented from the standpoint of safety. The safety profile ..." | ||
| Vol 16, No 1 (2020) | Control Of Anticoagulation Therapy in Atrial Fibrillation (COAT-AF Study) in Real Clinical Practice | Abstract similar documents |
| A. A. Zarudsky, A. A. Gavrilova, Т. S. Filinichenko | ||
| Vol 16, No 5 (2020) | New Pharmacogenetic Markers to Predict the Risk of Bleeding During Taking of Direct Oral Anticoagulants | Abstract PDF (Eng) similar documents |
| K. B. Mirzaev, D. V. Ivashchenko, I. V. Volodin, E. A. Grishina, K. A. Akmalova, A. A. Kachanova, A. I. Skripka, R. M. Minnigulov, T. E. Morozova, O. A. Baturina, A. N. Levanov, T. V. Shelekhova, A. I. Kalinkin, D. A. Napalkov, A. A. Sokolova, D. A. Andreev, I. N. Sychev, P. O. Bochkov, D. A. Sychev | ||
| "... and dabigatran for different indications: atrial fibrillation, endoprosthesis of large joints of lower limbs ..." | ||
| Vol 17, No 1 (2021) | Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Renal Dysfunction | Abstract similar documents |
| Z. D. Kobalava, A. A. Shavarov, M. V. Vatsik-Gorodetskaya | ||
| Vol 17, No 2 (2021) | Anticoagulant Therapy in Patients with Non-valvular Atrial Fibrillation in Real Clinical Practice: in Appropriate Dose Reductions | Abstract similar documents |
| V. A. Ionin, O. I. Bliznuk, E. I. Baranova, E. V. Shlyakhto | ||
| "... : rivaroxaban - 180/384 (46,9%) patients, dabigatran etexilate - 110/384 (28,6%) patients, apixaban - 94/384 (24 ..." | ||
| Vol 15, No 5 (2019) | Rivaroxaban-Associated Hepatotoxicity: a Clinical Case and Literature Review | Abstract similar documents |
| B. A. Tatarsky, N. V. Kazennova, D. A. Napalkov | ||
| Vol 8, No 1 (2012) | PHARMACOECONOMIC EVALUATION OF DABIGATRAN VS WARFARIN IN CARDIOVASCULAR EVENTS PREVENTION IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION | Abstract similar documents |
| Yu. B. Belousov, V. Yu. Mareev, I. S. Yavelov, D. Yu. Belousov | ||
| "... According to recent guidelines, oral dabigatran etexilate is indicated for stroke and systemic ..." | ||
| Vol 13, No 6 (2017) | PREDICTORS OF THE RISK OF HEMORRHAGIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION RECEIVING LONGTERM THERAPY WITH DIRECT ORAL ANTICOAGULANTS | Abstract similar documents |
| A. А. Sokolova, A. V. Zhilenko, I. L. Tsarev,, D. A. Napalkov, V. V. Fomin | ||
| "... and methods. 117 patients receiving DOAC (direct thrombin inhibitors – dabigatran, and Xa factor inhibitors ..." | ||
| Vol 11, No 1 (2015) | PHARMACOECONOMIC ASPECTS OF APIXABAN FOR PREVENTION OF THROMBOEMBOLIC EVENTS IN PATIENTS WITH ATRIAL FIBRILLATION | Abstract similar documents |
| A. V. Rudakova | ||
| "... , rivaroxaban and dabigatran. Along with clinical efficacy and safety profile one of the main characteristics ..." | ||
| Vol 15, No 6 (2019) | Safety of Non-Vitamin K Oral Anticoagulants in Elderly Patients with Atrial Fibrillation | Abstract similar documents |
| M. A. Gabitova, P. M. Krupenin, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... of age with confirmed AF, receiving dabigatran in a reduced dosage, apixaban or rivaroxaban in full ..." | ||
| Vol 16, No 1 (2020) | The Efficacy, Safety and Adherence to Treatment when New Anticoagulants Taking in Over 75 Years Old Patients with Atrial Fibrillation | Abstract similar documents |
| A. N. Turov, S. V. Panfilov, О. V. Tschiglinzeva | ||
| "... of the observation study was from 12 to 42 (26.9±4.9) months. Dabigatran was taken in 38.5% (n=166) of patients ..." | ||
| Vol 9, No 5 (2013) | APPLICATIONS OF PHARMACOGENETIC TESTING FOR PERSONALIZATION OF THERAPY WITH ORAL ANTICOAGULANTS IN RUSSIA | Abstract similar documents |
| D. A. Sychev, R. E. Kazakov, V. A. Otdelenov, A. B. Prokofiev | ||
| Vol 14, No 3 (2018) | THROMBOSIS OF LEFT ATRIAL APPENDAGE DURING THERAPY WITH DIRECT ORAL ANTICOAGULANT. CLINICAL CASE | Abstract similar documents |
| I. S. Daaboul, S. Yu. Koroleva, A. A. Kudrjavtseva, A. A. Sokolova, D. A. Napalkov, V. V. Fomin | ||
| "... , it was decided to replace apixaban with another direct oral anticoagulant – dabigatran 150 mg bid for a period ..." | ||
| Vol 14, No 4 (2018) | Hepatotoxicity of New Oral Anticoagulants | Abstract similar documents |
| A. R. Kasimova, A. V. Philippova (Guryanova), A. S. Kolbin | ||
| Vol 19, No 3 (2023) | Current insights into the possible role of laboratory monitoring of effectiveness and safety of direct oral anticoagulants | Abstract similar documents |
| S. R. Gilyarevsky, N. K. Vereina, M. V. Golshmid | ||
| Vol 20, No 4 (2024) | Should a physician use the Beers criteria when prescribing direct oral anticoagulants to elderly patients? | Abstract similar documents |
| N. M. Vorobyeva, I. P. Malaya, V. D. Zakiev, O. N. Tkacheva | ||
| Vol 12, No 5 (2016) | Features of Modern Anticoagulant Therapy in Patients with Nonvalvular Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| I. S. Daabul, A. A. Sokolova, D. A. Napalkov | ||
| Vol 18, No 6 (2022) | Left Ventricular Thrombosis: Current Perspective and Use of Direct Oral Anticoagulants | Abstract similar documents |
| A. D. Aga, A. A. Sokolova, D. A. Napalkov | ||
| Vol 17, No 4 (2021) | Effect of Direct Oral Anticoagulants for Ulcer Epithelization and Laser Doppler Flowmetry Parameters In Patients with Diabetic Foot Syndrome and Atrial Fibrillation | Abstract similar documents |
| V. I. Petrov, N. V. Rogova, T. N. Кuzmina, A. S. Lishuta | ||
| "... for DFS and rivaroxaban (group 1; n=24) or combination therapy for DFS and dabigatran (group 2; n=22 ..." | ||
| Vol 9, No 2 (2013) | ERA OF NEW ANTICOAGULANTS IN THE TREATMENT OF NON-VALVULAR ATRIAL FIBRILLATION: PROSPECTS AND CHALLENGES | Abstract similar documents |
| Z. M. Safiullina, S. V. Shalaev | ||
| "... Studies data on new anticoagulants, direct oral thrombin inhibitor (dabigatran) and direct ..." | ||
| Vol 12, No 2 (2016) | SYSTEMATIC REVIEW AND META-ANALYSIS: PITFALLS OF METHODS | Abstract similar documents |
| Yu. V. Lukina, S. Yu. Martsevich, N. P. Kutishenko | ||
| "... достоверные выводы. Поэтому использование систематических обзоров и мета-анализов высокого качества ..." | ||
| Vol 10, No 2 (2014) | SECONDARY PREVENTION OF STROKE IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION: THE CLINICIANS’ VIEWPOINT | Abstract similar documents |
| E. A. Drozdova | ||
| "... assessment of warfarin and dabigatran therapies is given. ..." | ||
| Vol 9, No 6 (2013) | THE ROLE OF P-GLYCOPROTEIN IN RATIONAL PHARMACOTHERAPY IN CARDIOLOGY | Abstract similar documents |
| A. V. Shulkin, E. N. Yakusheva, N. M. Popova | ||
| "... , prasugrel) and anticoagulants (dabigatran etexilate, rivaroxaban, edoxaban) is not feasible in routine ..." | ||
| Vol 11, No 3 (2015) | PHARMACOECONOMIC ASPECTS OF THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS AFTER LARGE JOINTS REPLACEMENT | Abstract similar documents |
| A. V. Rudakova | ||
| "... average prices of public bidding for the purchase of drugs (enoxaparin, dabigatran and apixaban) during ..." | ||
| Vol 8, No 2 (2012) | ADDITIONAL USE OF TRIMETAZIDINE IN PATIENTS WITH CHRONIC HEART FAILURE. A META-ANALYSIS | similar documents |
| Lei Zhang, Yizhou Lu, Hong Jiang, Liming Zhang, Aijun Sun, Yunzeng Zou, Junbo Ge | ||
| "... Цель. Целью мета-анализа было оценить эффекты дополнительного применения триметазидина (ТМЗ) при ..." | ||
| Vol 11, No 2 (2015) | ANTICOAGULANT THERAPY IN EVERYDAY CLINICAL PRACTICE: DATA OF THE RETROSPECTIVE CROSS-SECTIONAL STUDY | Abstract PDF (Eng) similar documents |
| V. A. Sulimov, D. A. Napalkov, A. A. Sokolova, A. V. Jilenko, O. S. Anikina | ||
| "... % of the patients received novel oral anticoagulants (dabigatran – 14%, rivaroxaban – 2%). Bleeding was fixed in 4 ..." | ||
| Vol 16, No 6 (2020) | The Oral Anticoagulants Administration in Elderly Patients with Geriatric Syndromes: What's New? | Abstract similar documents |
| N. M. Vorobyeva, O. N. Tkacheva | ||
| "... is presented. Most studies indicate significant advantages of direct oral anticoagulants (dabigatran ..." | ||
| Vol 17, No 5 (2021) | Gastrointestinal Bleeding: a Cardiologist's Point of View | Abstract similar documents |
| O. V. Averkov, L. N. Mishchenko | ||
| "... antagonists (warfarin) as well as direct oral anticoagulants (DOAC): dabigatran, rivaroxaban, apixaban ..." | ||
| Vol 7, No 3 (2011) | POTASSIUM INTAKE, STROKE, AND CARDIOVASCULAR DISEASE: A META-ANALYSIS OF PROSPECTIVE STUDIES | similar documents |
| L. D'Elia, G. Barba, F. P. Cappuccio, P. Strazzullo | ||
| "... результатов исследования, анализ в подгруппах и мета-регрессионный анализ. Результаты. Было выявлено ..." | ||
| Vol 7, No 6 (2011) | NEW ANTIARRHYTHMIC DRUG FOR THE TREATMENT OF ATRIAL FIBRILLATION. STUDY DATA, CLINICAL GUIDELINES, REGULATORY AGENCY RECOMMENDATIONS | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina | ||
| "... препаратов. По результатам мета-анализа рандомизированных клинических исследований, дронедарон уступает ..." | ||
| Vol 12, No 6 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract PDF (Eng) similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... стандартной терапией венозных тромбоэмболических осложнений (ВТЭО). Материал и методы. Выполнен мета-анализ ..." | ||
| Vol 12, No 1 (2016) | Efficacy and safety of the new oral anticoagulants in the treatment of venous thromboembolic complications: meta-analysis | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, V. S. Gorbatenko, O. N. Smuseva, A. S. Maslakov | ||
| "... стандартной терапией венозных тромбоэмболических осложнений (ВТЭО). Материал и методы. Выполнен мета-анализ ..." | ||
| Vol 18, No 3 (2022) | Risk of Venous Thromboembolic Complications in Patients with Atrial Fibrillation: a Systematic Review and Meta-analysis | Abstract PDF (Eng) similar documents |
| A. A. Sokolova, A. A. Kudriavtseva, N. V. Kostokova, M. P. Zaikina, Z. A. Gebekova, D. A. Napalkov, I. A. Zolotukhin | ||
| Vol 18, No 1 (2022) | Modern Anticoagulant Therapy for Atrial Fibrillation: Patient Adherence in Clinical Practice | Abstract similar documents |
| Yu. P. Skirdenko, N. A. Nikolaev, K. G. Pereverzeva, A. Yu. Timakova, A. S. Galus, S. S. Yakushin | ||
| "... .6%) and dabigatran (17.3%) and warfarin (19.4%) were prescribed almost twice as rarely as rivaroxaban ..." | ||
| Vol 17, No 5 (2021) | Genetic Polymorphism of beta1-adrenergic Receptors and the Effect on the Clinical Efficacy of beta-adrenoblockers | Abstract similar documents |
| V. N. Larina, M. V. Leonova | ||
| "... пациентов с ХСН с носительством вариантного аллеля Gly389. По данным двух мета-анализов клинических ..." | ||
| Vol 18, No 4 (2022) | N-acetylcysteine in the Prevention of Contrast-induced Acute Kidney Injury: a Systematic Review and Meta-analysis of Randomized Controlled Clinical Trials | Abstract similar documents |
| E. M. Mezhonov, Yu. A. Vyalkina, S. V. Shalaev | ||
| "... повреждения (КИ-ОПП). Материал и методы. Мета-анализ выполнен в соответствии с рекомендациями PRISMA на ..." | ||
| Vol 9, No 2 (2013) | A META-ANALYSIS REPORTING EFFECTS OF ANGIOTENSIN-CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN PATIENTSWITHOUT HEART FAILURE | Abstract similar documents |
| G. Savarese, P. Costanzo, J.G.F. Cleland, E. Vassallo, D. Ruggiero, G. Rosano, P. Perrone-Filardi | ||
| "... время как эффект БРА является менее определенным. Материал и методы. В мета-анализ было включено 26 ..." | ||
| Vol 16, No 1 (2020) | Clinical Significance of Thrombin Blockade with Low Doses (2.5 mg) of Rivaroxaban in Ischemic Heart Disease Patients | Abstract similar documents |
| A. B. Sumarokov, L. I. Buryachkovskaya, Y. V. Docenko, M. S. Kurochkin, N. V. Lomakin | ||
| "... therapy turned out to be the most promising for clinical use, since studies with dabigatran and apixaban ..." | ||
| Vol 15, No 3 (2019) | Genetic, Epigenetic and Transcription Factors in Atrial Fibrillation | Abstract similar documents |
| O. V. Sapelnikov, A. A. Kulikov, O. O. Favorova, N. A. Matveeva, D. I. Cherkashin, O. A. Nikolaeva, R. S. Akchurin | ||
| "... среды и множеством аллелей. В последние годы появление полногеномного ассоциативного сканирования ..." | ||
| Vol 13, No 5 (2017) | WARFARIN AND ITS IMPORTANCE IN THE ERA OF NEW ORAL ANTICOAGULANTS. ISSUES OF MONITORING THE EFFECTIVENESS AND SAFETY OF TREATMENT | Abstract similar documents |
| S. Yu. Martsevich, Y. V. Lukina | ||
| "... of new OAC (NOAC) also appeared. In Russia, dabigatran, rivaroxaban and apixaban have been registered ..." | ||
| Vol 17, No 5 (2021) | Efficiency of the Left Atrial Appendage Thrombus Dissolution in Patients with Persistent Nonvalvular Atrial Fibrillation with Warfarin or Direct Oral Anticoagulants Therapy | Abstract PDF (Eng) similar documents |
| E. S. Mazur, V. V. Mazur, N. D. Bazhenov, Yu. A. Orlov | ||
| "... at the level of 2-3, 14 (20.6%) started or continued taking dabigatran at a dose of 150 mg 2 times/day, 14 (20 ..." | ||
| Vol 21, No 2 (2025) | Anticoagulant therapy in patients with cardioembolic subtype of ischemic stroke and atrial fibrillation | Abstract similar documents |
| E. A. Naryshkina, M. I. Chashkina, E. S. Zadykyan, N. K. Kurbanalieva, E. M. Zakaryan, M. V. Serova, D. A. Andreev, A. G. Komarova, K. E. Eroshkin, A. A. Kulesh, D. A. Sychev | ||
| "... on outpatient ACT were included; rivaroxaban (n=56), apixaban (n=30), dabigatran etexilate (n=11), and warfarin ..." | ||
| Vol 14, No 1 (2018) | NUCLEAR IMAGING IN THE DIAGNOSIS OF CARDIAC AMYLOIDOSIS | Abstract similar documents |
| V. B. Sergienko, S. N. Tereshchenko, A. A. Ansheles, I. V. Zhirov, A. A. Safiullina | ||
| Vol 10, No 3 (2014) | COST-EFFECTIVENESS OF APIXABAN AS COMPARED WITH WARFARIN AND ACETYLSALICYLIC ACID IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN THE RUSSIAN FEDERATION | Abstract similar documents |
| A. V. Rudakova, V. A. Parfenov | ||
| "... anticoagulants such as apixaban, rivaroxaban and dabigatran. Administration of vitamin K antagonists (VKA ..." | ||
| Vol 15, No 6 (2019) | Adherence to Treatment with New Oral Anticoagulants in Atrial Fibrillation Patients in Real Clinical Practice (Results of the ANTEY Study) | Abstract similar documents |
| S. Yu. Martsevich, Yu. V. Lukina, N. P. Kutishenko, S. N. Tolpygina, V. P. Voronina, N. A. Dmitrieva, O. V. Lerman, N. A. Komkova | ||
| "... recommended the use of rivaroxaban; 47 (23.4%) – the use of dabigatran and 43 (21.4%) – the use of apixaban ..." | ||
| Vol 9, No 4 (2013) | STATINS IN PREVENTION OF ISCHEMIC STROKE | Abstract similar documents |
| A. V. Susekov, A. B. Blohin, Z. G. Luginova, E. J. Soloveva, N. V. Maltseva, O. E. Tarasova, V. V. Kuharchuk | ||
| "... ишемического инсульта, так и результаты мета-анализов. ..." | ||
| Vol 4, No 3 (2008) | ROLE OF BETA-ADRENOBLOCKERS IN ARTERIAL HYPERTENSION TREATMENT. WHAT DO EVIDENCE BASED MEDICINE DATA SHOW? | Abstract similar documents |
| S. Y. Martsevich | ||
| "... исследований и мета-анализов. ..." | ||
| Vol 5, No 1 (2009) | ONCE AGAIN ABOUT BETA-ADRENOBLOCKERS IN ARTERIAL HYPERTENSION. WHAT SHOULD DOCTOR RECOMMEND TO THE PATIENT? | Abstract similar documents |
| S. Y. Martsevich | ||
| "... медицины и международных клинических рекомендаций. Представлены данные последних мета-анализов ..." | ||
| Vol 9, No 2 (2013) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: ISN'T IT TIME TO DRAW A LINE UNDER DISCUSSION ABOUT SUPERIORITY | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... Комментарий к статье G. Savarese et al. Мета-анализ исследований, сообщавших об эффектах ..." | ||
| Vol 20, No 5 (2024) | Effectiveness and safety of direct oral anticoagulants in patients with atrial fibrillation and chronic kidney disease: a systematic review and meta-analysis of clinical trials | Abstract similar documents |
| E. M. Mezhonov, Z. M. Safiullina, Y. A. Vyalkina, S. V. Shalaev | ||
| "... " or "dabigatran" or "apixaban" or "rivaroxaban" and "vitamin K antagonist" or "warfarin" and "outcomes". ROBINS-I ..." | ||
| Vol 4, No 1 (2008) | ACUTE CEREBROVASCULAR EVENTS IN PATIENTS WITH ARTERIAL HYPERTENSION: MOLECULAR GENETIC ASPECTS | Abstract similar documents |
| M. A. Karpenko, E. G. Shatskaya, V. N. Solntsev, M. A. Bogdanov, V. I. Larionova | ||
| "... полиморфизмом гена Fb и С677Т полиморфизмом гена MTHFR. При этом маркерами повышенного риска выступают С-аллель ..." | ||
| Vol 9, No 4 (2013) | ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS: IS THERE A REASON TO CONSIDER AN EQUIVALENCE OF TWO DRUG CLASSES FROM THE EVIDENCE BASED MEDICINE STANDPOINT | Abstract similar documents |
| S. Yu. Martsevich | ||
| "... . Приводит данные последних мета-анализов, сравнивающих влияние ИАПФ и АРА на прогноз жизни больных с высоким ..." | ||
| Vol 8, No 1 (2012) | BETA-BLOCKERS IN THE TREATMENT OF ARTERIAL HYPERTENSION: EVIDENCE BASED DATA AND REAL PRACTICE | Abstract similar documents |
| M. V. Leonova | ||
| "... Представлены данные наиболее крупных мета-анализов применения бета-адреноблокаторов (БАБ) при ..." | ||
| Vol 4, No 3 (2008) | ANTITHROMBOTIC THERAPY AT PERCUTANEOUS CORONARY INTERVENTIONS | Abstract similar documents |
| V. A. Sulimov | ||
| "... рандомизированных клинических исследо- ваний и мета-анализов, посвященных данной проблеме. Рассматриваются ..." | ||
| Vol 9, No 4 (2013) | VARENICLINE IN PATIENTS WITH CARDIOVASCULAR DISEASES – FRIEND OR ENEMY? | Abstract similar documents |
| Yu. V. Lukina, S. Yu. Martsevich | ||
| "... крупных клинических исследований с варениклином, данные их мета-анализов, доказали высокую эффективность ..." | ||
| Vol 18, No 3 (2022) | Study the Association of Nucleotide Polymorphisms in Platelet Receptor and Cytochrome P450 Genes with the Development of Resistance to Antiplatelet Drugs in Patients with Coronary Artery Disease | Abstract similar documents |
| K. S. Semashchenko, T. S. Mongush, A. A. Kosinova, T. N. Subbotina, Y. I. Grinshtein | ||
| "... ДНК была проведена аллель-специфичная ПЦР для выявления полиморфизмов rs2046934, rs1126643, rs5918, rs ..." | ||
| Vol 7, No 3 (2011) | REDUCTION DEGREE OF LOW-DENSITY LIPOPROTEINS CHOLESTEROL LEVELS ACCORDING TO DIFFERENT DOSES OF STATINS; ITS EFFECT ON THE RISK OF ISCHEMIC HEART DISEASE ACUTE EPISODES DEPENDING ON TREATMENT DURATION; AND RISK OF ISCHEMIC AND THROMBOEMBOLIC STROKE. COMMENT ON THE PAPER OF LAW M.R., WALD N.J., RUDNICKA A.R. QUANTIFYING EFFECT OF STATINS ON LOW DENSITY LIPOPROTEIN CHOLESTEROL, ISCHAEMIC HEART DISEASE, AND STROKE: SYSTEMATIC REVIEW AND META-ANALYSIS. BMJ 2003; 326:1423-1427 | Abstract similar documents |
| N. V. Perova | ||
| "... В трёх крупных мета-анализах была определена сравнительная дозозависимая способность различных ..." | ||
| Vol 3, No 3 (2007) | REDUCTION OF CUMULATIVE CARDIOVASCULAR RISK IN PATIENTS WITH ARTERIAL HYPERTENSION: THE ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS ACCORDING TO THE NEW EUROPEAN RECOMMENDATIONS | Abstract similar documents |
| M. N. Mamedov, N. A. Chepurina, Z. N. Tokareva, A. A. Evdokimova | ||
| "... терапии основан на мета-анализе крупных клинических исследований с твердыми конечными точками ..." | ||
| Vol 6, No 3 (2010) | ASSOCIATION OF CLINICAL AND GENETIC FACTORS WITH LEFT VENTRICLE HYPERTROPHY IN ARTERIAL HYPERTENSION | Abstract PDF (Eng) similar documents |
| T. Yu. Kuznetsova, D. V. Gavrilov, L. M. Samohodskaya, D. V. Rebrikov, S. A. Morozova, P. I. Makarevich, A. V. Kolotvin, A. B. Balatsky, A. Yu. Postnov, S. A. Boitsov | ||
| "... , а по заменам М235Т, G(-6)A гена ангиотензиногена с помощью аллель-специфичной ПЦР «в реальном ..." | ||
| Vol 20, No 5 (2024) | Association between renin-angiotensin system gene polymorphism and cardio-ankle vascular index in patients with COVID-19 | Abstract similar documents |
| V. I. Podzolkov, A. E. Bragina, E. S. Ogibenina, I. I. Shvedov, A. R. Komelkova | ||
| "... -лодыжечного индекса (Cardio-Ankle Vascular Index, CAVI) методом сфигмоманометрии и идентифицированы аллели и ..." | ||
| Vol 10, No 5 (2014) | STATINS IN THE TREATMENT AND PREVENTION OF CARDIOVASCULAR DISEASES: REPETITION OF THE PAST AND OPTIMISM FOR THE FUTURE | Abstract similar documents |
| L. N. Malay | ||
| "... достижения с фокусом на розувастатин. Представлены данные последних мета-анализов, продемонстрировавших ..." | ||
| Vol 9, No 5 (2013) | THE ROLE OF LIPOTROPIC THERAPY IN PATIENTS WITH CHRONIC ISCHEMIC HEART DISEASE BEFORE AND AFTER CORONARY REVASCULARIZATION | Abstract similar documents |
| R. N. Adzhiev, M. S. Safarova, M. V. Ezhov | ||
| "... результаты крупных исследований (LIPS, ARMYDA, NAPLES II, ARMYDA-RECAPTURE, Post-CABG, TNT) и мета-анализов ..." | ||
| Vol 19, No 3 (2023) | Association of polymorphic variants of CYP2C19, P2RY12, ITGB3, ITGA2 and eNOS3 genes with high residual platelet reactivity while taking clopidogrel and acetylsalicylic acid at different terms of myocardial infarction | Abstract similar documents |
| T. P. Pronko, V. A. Snezhitskiy, T. L. Stepuro, A. V. Kapytski | ||
| "... носителей аллеля 681A гена CYP2C19 риск развития ВОРТ к клопидогрелу выше, по сравнению с носителями аллеля ..." | ||
| Vol 17, No 4 (2021) | Association of SCN5A gene polymorphism with dilated cardiomyopathy | Abstract similar documents |
| S. Yu. Nikulina, O. O. Kuznetsova, A. A. Chernova, G. V. Matyushin, A. A. Gurazheva, V. N. Maksimov | ||
| "... сравнению с контрольной группой. В группе пациентов с ДМИГ аллель А (69,5% против 80,1%, p=0,003) и генотип ..." | ||
| Vol 18, No 4 (2022) | The effect of rs776746 polymorphism in the CYP3A5 gene on heart rate when using bisoprolol in patients with acute coronary syndrome | Abstract similar documents |
| V. A. Shumkov, K. A. Zagorodnikova, S. A. Boldueva, A. A. Murzina | ||
| "... (возраст 63,5±10,5 года; 60 мужчин и 37 женщин). Частота искомых аллелей гена CYP3A5 составила: CYP3A5*3 ..." | ||
| Vol 8, No 6 (2012) | MODERN VIEWS ON THE VARIABILITY OF BLOOD PRESSURE | Abstract similar documents |
| V. M. Gorbunov | ||
| "... к визиту». Ретроспективный мета-анализ показал, что в когортах пациентов, перенесших мозговой ..." | ||
| Vol 13, No 4 (2017) | HIGH DOSES OF STATINS BEFORE PERCUTANEOUS CORONARY INTERVENTION: WHETHER THERE ARE REASONS TO USE? | Abstract similar documents |
| I. S. Yavelov, M. V. Zhatkina, O. M. Drapkina, A. Yu. Gorshkov, N. O. Myasnikova | ||
| "... данные мета-анализов проведенных клинических испытаний. Согласно накопленным фактам, прием высоких доз ..." | ||
| Vol 15, No 5 (2019) | Adverse Reactions of the Cardiovascular System when Taking Nonsteroidal Anti-inflammatory Drugs and Ways to Reduce Them | Abstract similar documents |
| N. V. Pyrikova, O. N. Antropova, I. V. Osipova | ||
| "... исследований российских и зарубежных авторов и мета-анализов действия НПВП на профиль артериального давления ..." | ||
| Vol 15, No 6 (2019) | Glycoprotein IIb/IIIa Receptor Inhibitors in Patients with ST-Segment Elevation Myocardial Infarction and Primary Percutaneous Coronary Intervention | Abstract similar documents |
| A. S. Tereshchenko, Е. V. Merkulov, A. M. Samko | ||
| "... сегмента ST. В то время как уже существует мета-анализ по рутинному применению ингибиторов гликопротеиновых ..." | ||
| Vol 16, No 1 (2020) | High Blood Pressure Variability is an Additional Cardiovascular Risk Factor | Abstract similar documents |
| A. V. Rodionov | ||
| "... — независимый прогностический фактор, увеличивающий риск сердечно-сосудистых осложнений. В крупнейшем мета ..." | ||
| Vol 16, No 3 (2020) | New Variant of MYH7 Gene Nucleotide Sequence in Familial Non-Compaction Cardiomyopathy with Benign Course | Abstract PDF (Eng) similar documents |
| R. P. Myasnikov, O. V. Kulikova, A. N. Meshkov, A. V. Kiseleva, A. O. Shumarina, S. N. Koretskiy, A. A. Zharikova, M. G. Divashuk, M. S. Kharlap, S. E. Serduk, E. A. Mershina, V. E. Sinitsyn, S. A. Boytsov, O. M. Drapkina | ||
| "... . Проведен сравнительный анализ полученных данных с результатами последних крупных исследований и мета ..." | ||
| Vol 16, No 3 (2020) | Treatment of Hypertension: Is There a Place for Personalization of the Approach in Modern Recommendations? | Abstract similar documents |
| V. I. Podzolkov, A. E. Bragina, Yu. N. Rodionova | ||
| "... комбинированной терапии, подтвержденные результатами рандомизированных клинических исследований и мета-анализов ..." | ||
| Vol 16, No 4 (2020) | Current Clinical and Pharmacological Approaches to the Prescription of Loop Diuretics in Patients with Chronic Heart Failure | Abstract similar documents |
| N. M. Gafurova, E. V. Shikh, O. D. Ostroumova | ||
| "... мета-анализ показал, что у пациентов с ХСН петлевые и тиазидные диуретики могут снизить риск смерти и ..." | ||
| Vol 15, No 1 (2019) | New Guidelines on Management of Arterial Hypertension: Key Similarities and Differences | Abstract similar documents |
| Zh. D. Kobalava, E. A. Troitskaya, E. L. Kolesnik | ||
| "... разную трактовку результатов одних и тех же исследований и мета-анализов. Нет сомнений в необходимости ..." | ||
| Vol 15, No 4 (2019) | Safety of Using Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Chronic Kidney Disease | Abstract similar documents |
| V. I. Petrov, O. V. Shatalova, A. S. Gerasimenko, V. S. Gorbatenko | ||
| "... ишемических инсультов. При анализе клинических рекомендаций, рандомизированных исследований, мета-анализов и ..." | ||
| 1 - 100 of 120 Items | 1 2 > >> | |
Search tips:
- Search terms are case-insensitive
- Common words are ignored
- By default articles containing any term in the query are returned (i.e., OR is implied)
- Make sure that a word exists in an article by prefixing it with +; e.g., +journal +access scholarly academic
- Combine multiple words with AND to find articles containing all terms; e.g., education AND research
- Exclude a word by prefixing it with - or NOT; e.g., online -politics or online NOT politics
- Search for an exact phrase by putting it in quotes; e.g., "open access publishing". Hint: Quoting Chinese or Japanese words will help you to find exact word matches in mixed-language fields, e.g. "中国".
- Use parentheses to create more complex queries; e.g., archive ((journal AND conference) NOT theses)
